These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32749106)

  • 1. Paradoxical Role of Dengue Virus Envelope Protein Domain III Antibodies in Dengue Virus Infection.
    Ali S; Afzal S; Yousaf MZ; Shahid M; Amin I; Idrees M; Aftab A
    Crit Rev Eukaryot Gene Expr; 2020; 30(3):199-206. PubMed ID: 32749106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
    Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
    Tsai WY; Lai CY; Wu YC; Lin HE; Edwards C; Jumnainsong A; Kliks S; Halstead S; Mongkolsapaya J; Screaton GR; Wang WK
    J Virol; 2013 Dec; 87(23):12562-75. PubMed ID: 24027331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural strain variation and antibody neutralization of dengue serotype 3 viruses.
    Wahala WM; Donaldson EF; de Alwis R; Accavitti-Loper MA; Baric RS; de Silva AM
    PLoS Pathog; 2010 Mar; 6(3):e1000821. PubMed ID: 20333252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.
    Williams KL; Wahala WM; Orozco S; de Silva AM; Harris E
    Virology; 2012 Jul; 429(1):12-20. PubMed ID: 22537810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.
    Wahala WM; Kraus AA; Haymore LB; Accavitti-Loper MA; de Silva AM
    Virology; 2009 Sep; 392(1):103-13. PubMed ID: 19631955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.
    Wahala WM; Huang C; Butrapet S; White LJ; de Silva AM
    J Virol; 2012 Apr; 86(7):4019-23. PubMed ID: 22278250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.
    Young E; Carnahan RH; Andrade DV; Kose N; Nargi RS; Fritch EJ; Munt JE; Doyle MP; White L; Baric TJ; Stoops M; DeSilva A; Tse LV; Martinez DR; Zhu D; Metz S; Wong MP; Espinosa DA; Montoya M; Biering SB; Sukulpolvi-Petty S; Kuan G; Balmaseda A; Diamond MS; Harris E; Crowe JE; Baric RS
    Cell Host Microbe; 2020 May; 27(5):710-724.e7. PubMed ID: 32407709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
    de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
    Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
    Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
    mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Engineered N-Glycosylated Dengue Envelope Protein Domain III Facilitates Epitope-Directed Selection of Potently Neutralizing and Minimally Enhancing Antibodies.
    Nilchan N; Kraivong R; Luangaram P; Phungsom A; Tantiwatcharakunthon M; Traewachiwiphak S; Prommool T; Punyadee N; Avirutnan P; Duangchinda T; Malasit P; Puttikhunt C
    ACS Infect Dis; 2024 Aug; 10(8):2690-2704. PubMed ID: 38943594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preparation and identification of neutralizing antibodies to envelope protein domain III(ED III) of the four dengue virus serotypes].
    Ding X; Qiu L; Chen Y; Wen K
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Aug; 38(8):748-753. PubMed ID: 35851089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
    Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
    J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
    Sukupolvi-Petty S; Austin SK; Purtha WE; Oliphant T; Nybakken GE; Schlesinger JJ; Roehrig JT; Gromowski GD; Barrett AD; Fremont DH; Diamond MS
    J Virol; 2007 Dec; 81(23):12816-26. PubMed ID: 17881453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.
    Gallichotte EN; Young EF; Baric TJ; Yount BL; Metz SW; Begley MC; de Silva AM; Baric RS
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.